Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?

Antimicrob Agents Chemother. 2021 May 18;65(6):e00430-21. doi: 10.1128/AAC.00430-21. Print 2021 May 18.

Ruth Van Daele^{1

2}, Yves Debaveye^{3

4}, Katrien Lagrou^{5

6

7}, Isabel Spriet^{8

2}

¹ Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
² Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
³ Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
⁴ Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
⁵ Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
⁶ National Reference Centre for Mycosis, Excellence Centre for Medical Mycology (ECMM), University Hospitals Leuven, Leuven, Belgium.
⁷ Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
⁸ Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium isabel.spriet@uzleuven.be.

No abstract available

Keywords: antifungals; candidemia; critically ill; exposure; invasive candidiasis; pharmacokinetics.

Publication types